BRIEF: Everest unveils positive results for kidney drug EVER001 in Phase 1b/2a trial
Everest Medicines (1952.HK) announced on Wednesday that its EVER001, a next-generation covalent reversible Bruton’s tyrosine kinase (BTK) inhibitor for treatment of primary membranous nephropathy (pMN), showed positive results in its…
RELATED ARTICLES
-
Everest Medicines drives growth with AI-powered mRNA pipeline
1952.HK -
Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
1952.HK
-
A blockbuster cancer drug? TYK’s claims go under the microscope
2410.HK
-
Futu layoffs signal new phase of consolidation after rapid expansion
FUTU.US
- Cancer drug maker Genfleet joins Hong Kong IPO influx
